Northern Trust
NMRA icon

Northern Trust’s Neumora Therapeutics NMRA Stock Holding History

Northern Trust’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
800,571
+603,690
+307% +$1.15M ﹤0.01% 3345
2026
Q1 		$384K Buy
196,881
+11,520
+6% +$29.9K ﹤0.01% 3715
2025
Q4 		$332K Buy
185,361
+27,555
+17% +$60.3K ﹤0.01% 3798
2025
Q3 		$287K Sell
157,806
-17,590
-10% -$28.4K ﹤0.01% 3844
2025
Q2 		$129K Sell
175,396
-513,855
-75% -$389K ﹤0.01% 4055
2025
Q1 		$689K Sell
689,251
-45,596
-6% -$78.1K ﹤0.01% 3436
2024
Q4 		$7.79M Buy
734,847
+52,464
+8% +$629K ﹤0.01% 2270
2024
Q3 		$9.01M Buy
682,383
+542,746
+389% +$6.33M ﹤0.01% 2127
2024
Q2 		$1.37M Buy
139,637
+18,246
+15% +$189K ﹤0.01% 3098
2024
Q1 		$1.67M Sell
121,391
-5,053
-4% -$81.7K ﹤0.01% 3054
2023
Q4 		$2.16M Buy
+126,444
New +$1.55M ﹤0.01% 2965

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Northern Trust's NMRA Position: Q2 2026 in Review

Northern Trust increased its Neumora Therapeutics (NMRA) stake by 307% in Q2 2026, buying an estimated $1.15M and bringing the position to 800,571 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3345.

Northern Trust first reported a position in NMRA in Q4 2023 and has held it in 11 quarters since. The position peaked at $9.01M in Q3 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Northern Trust held 800,571 shares of Neumora Therapeutics worth $1.36M as of Q2 2026.
  • Northern Trust bought 603,690 Neumora Therapeutics shares in Q2 2026, an estimated $1.15M.
  • Neumora Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3345 holding.
  • Northern Trust first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Northern Trust's Neumora Therapeutics position peaked at $9.01M in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.